Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 2/20 | 0.52 |
| ▸ | CNR2 | P34972 | 7/20 | 0.45 |
| ▸ | CNR1 | P21554 | 5/20 | 0.45 |
| ▸ | EGFR | P00533 | 1/20 | 0.43 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.40 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.40 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.40 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | TLR4 | O00206 | 1/20 | 0.39 |
| ▸ | TLR2 | O60603 | 1/20 | 0.39 |
| ▸ | BCHE | P06276 | 2/20 | 0.39 |
| ▸ | NAE1 | Q13564 | 1/20 | 0.38 |
| ▸ | UBA3 | Q8TBC4 | 1/20 | 0.38 |
| ▸ | KDR | P35968 | 1/20 | 0.37 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5319746 | 0.84 | EGFR (0.53) | RAB9AEGFRNPC1MAPTSMN1; SMN2 | |
| SCHEMBL2453535 | 0.82 | KDR (0.58) | EGFRKDR | |
| SCHEMBL12303607 | 0.82 | KDR (0.58) | EGFRKDR | |
| SCHEMBL2453533 | 0.82 | KDR (0.58) | EGFRKDR | |
| SCHEMBL2454298 | 0.81 | MAOA (0.39) | CNR2CNR1EGFR | |
| SCHEMBL2450814 | 0.81 | NPC1 (0.48) | RAB9AEGFRNPC1MAPT | |
| SCHEMBL2454013 | 0.80 | MAOB (0.48) | RAB9AEGFRNPC1MAPTSMN1; SMN2 | |
| SCHEMBL2453807 | 0.80 | CDC7 (0.52) | EGFR | |
| SCHEMBL2451281 | 0.80 | MAOB (0.50) | EGFRSMN1; SMN2 | |
| SCHEMBL2450854 | 0.80 | MAP3K7 (0.51) | EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2007109783-A2 | SUBSTITUTED PYRIMIDINE KINASE INHIBITORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-09-27 | — | — | WO | claimed |
| US-8013153-B2 | Substituted pyrimidine kinase inhibitors | JANSSEN PHARMACEUTICA, N.V. (BE) | 2011-09-06 | — | — | US | disclosed |
| US-20070254896-A1 | SUBSTITUTED PYRIMIDINE KINASE INHIBITORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-11-01 | — | — | US | disclosed |
| WO-2007109783-A2 | SUBSTITUTED PYRIMIDINE KINASE INHIBITORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-09-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070254896-A1 | SUBSTITUTED PYRIMIDINE KINASE INHIBITORS | DTYMK, TK1, DCK | RAB9A 2802/4885CNR2 2088/4885CNR1 1946/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.